Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Puma Biotechnology Inc | PUMA-ALI-1201 - (ALISCA-Breast1) | HER-2 Recurrent or metastatic breast cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Puma Biotechnology Inc | Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1) | Small Cell Lung Cancer (SCLC) | Phase 2 | Data Released | Oral | Oncology |
| Puma Biotechnology Inc | Alisertib (PUMA-ALI-4201) in combination with endocrine treatment - (ALISCA-Breast1) | HER2-negative, hormone receptor-positive metastatic breast cancer | Phase 2 | IND Clearance | Oral | Oncology |
| Puma Biotechnology Inc | Paclitaxel and Alisertib | Breast Cancer | Phase 2 | Type Meeting | Intravenous | Oncology |
| Puma Biotechnology Inc | NERLYNX (Neratinib) - (BASKET) | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | Phase 2 | Trial Planned | Oral | Oncology |
| Puma Biotechnology Inc | NERLYNX (neratinib) | Glioblastoma (GBM) | Phase 2 | Trial Completed | Oral | Oncology |
| Puma Biotechnology Inc | NERLYNX (neratinib) and Xeloda (capecitabine) | HER2-negative breast cancer | Phase 2 | Trial Planned | Oral | Oncology |
| Puma Biotechnology Inc | KADCYLA (trastuzumab emtansine) plus NERLYNX (Neratinib) - (TBCRC-022) | HER2 positive breast cancer with brain metastases | Phase 2 | Ongoing | Intravenous and oral | Oncology |
